M
Mitsuhiro Takenoyama
Researcher at University of Occupational and Environmental Health Japan
Publications - 230
Citations - 4540
Mitsuhiro Takenoyama is an academic researcher from University of Occupational and Environmental Health Japan. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 36, co-authored 221 publications receiving 3884 citations. Previous affiliations of Mitsuhiro Takenoyama include Kyushu University.
Papers
More filters
Journal ArticleDOI
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito Okada,Takashi Kijima,Keisuke Aoe,Terufumi Kato,Nobukazu Fujimoto,Kazuhiko Nakagawa,Yuichiro Takeda,Toyoaki Hida,Kuninobu Kanai,Fumio Imamura,Satoshi Oizumi,Toshiaki Takahashi,Mitsuhiro Takenoyama,Hiroshi Tanaka,Jun Hirano,Yoshinobu Namba,Yuichiro Ohe +16 more
TL;DR: Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity and adverse events and treatment-related AEs.
Journal ArticleDOI
Prognostic Impact of Micrometastatic Tumor Cells in the Lymph Nodes and Bone Marrow of Patients With Completely Resected Stage I Non–Small-Cell Lung Cancer
Toshihiro Osaki,Tsunehiro Oyama,Chundong Gu,Toshihiro Yamashita,Tomoko So,Mitsuhiro Takenoyama,Kenji Sugio,Kosei Yasumoto +7 more
TL;DR: The detection of lymph nodal micrometastatic tumor cells provides an accurate assessment of tumor staging and has powerful prognostic implications for completely resected stage I NSCLC patients.
Journal ArticleDOI
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Takamitsu Onitsuka,Hidetaka Uramoto,Naohiro Nose,Mitsuhiro Takenoyama,Takeshi Hanagiri,Kenji Sugio,Kosei Yasumoto +6 more
TL;DR: The T790M mutation in the EGFR is relatively common in the patients with acquired resistance to gefitinib, however, mechanisms other than T790m, MET, and HGF status are involved in resistance togefit inib.
Journal ArticleDOI
Haplotype Loss of HLA Class I Antigen as an Escape Mechanism from Immune Attack in Lung Cancer
Tetsuya So,Mitsuhiro Takenoyama,Makiko Mizukami,Yoshinobu Ichiki,Masakazu Sugaya,Takeshi Hanagiri,Kenji Sugio,Kosei Yasumoto +7 more
TL;DR: It is hypothesized that the majority of tumor cells with normal HLA class I expression were attacked and eradicated by CTLs, and only a minority with an abnormal expression of HLAclass I antigens could escape the host's immunosurveillance system.
Journal ArticleDOI
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Kenji Sugio,Hidetaka Uramoto,Takamitsu Onitsuka,Makiko Mizukami,Yoshinobu Ichiki,Masakazu Sugaya,Manabu Yasuda,Mitsuhiro Takenoyama,Tsunehiro Oyama,Takeshi Hanagiri,Kosei Yasumoto +10 more
TL;DR: EGFR mutations in exons 19 or 21 are considered to be a good predictor of the efficacy of gefitinib, and four of five acquired resistant tumors showed an acquired T790M mutation.